Program
suzetrigine
Also written as “Suzetrigine”, “VX-548” and “SUZ”.
Its studies are mostly in Pain · Acute Pain · Neuralgia · Radiculopathy, led by 2 companies.
Drug pageSuzetrigine: every studyAll 57 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticalsits history only | 263 open or running | phase 4since Mar 19, 2025 | Jul 15, 2021 | Jan 25, 2027phase 3 · NCT06696443 |
| Latigo Biotherapeuticsits history only | 10 open or running | early phase 1since May 6, 2025 | May 6, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jul 15, 2021.
- Jan 19, 2023Phase 1 study in PainVertex Pharmaceuticals · NCT05704556 · 38 enrolled · United States
- Jan 19, 2023Named suzetrigineINNProposed as its International Nonproprietary Name in WHO's List 128 · before, VX-548
- Apr 5, 20232 phase 1 studies in PainVertex Pharmaceuticals · NCT05818852, NCT05851157
- Dec 10, 2023Phase 2 study in Painful Lumbosacral RadiculopathyVertex Pharmaceuticals · NCT06176196 · 218 enrolled · United States
- Mar 21, 2024Phase 1 study in PainVertex Pharmaceuticals · NCT06336096 · 48 enrolled · United States
- May 14, 2024Phase 1 study in PainVertex Pharmaceuticals · NCT06420765 · 92 enrolled · United Kingdom
- Sep 30, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06628908 · 1,100 planned · United States
- Nov 15, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06696443 · 455 enrolled · United States
- Feb 5, 20252 phase 1 studies in PainVertex Pharmaceuticals · NCT06820307, NCT06834009
- Mar 19, 20252 phase 4 studies in Acute PainVertex Pharmaceuticals · NCT06887972, NCT06887959
- May 6, 2025Latigo Biotherapeutics’ first study: early phase 1 study in Pain DetectionNew to Latigo BiotherapeuticsLatigo Biotherapeutics · NCT06972212 · 20 enrolled · New Zealand
- Nov 13, 2025Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT07231419 · 734 planned · United States
- Jan 23, 2026Phase 1 study in PainVertex Pharmaceuticals · NCT07378865 · 13 enrolled · United States
- Apr 13, 2026Phase 4 study in PainVertex Pharmaceuticals · NCT07538570 · 66 enrolled · United States
- Apr 29, 2026Phase 1 study in PainVertex Pharmaceuticals · NCT07570069 · 18 enrolled · United States
Ahead
- Jan 25, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06696443
- Apr 6, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT07231419
- May 31, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06628908
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07570069Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jul 16, 2026 | 18 |
| NCT07538570Pain · United States | 4 | Completed | Vertex Pharmaceuticals | Oct 12, 2026 | 66 |
| NCT07378865Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Aug 17, 2026 | 13 |
| NCT07231419Diabetic Peripheral Neuropathic Pain · United States | 3 | Recruiting | Vertex Pharmaceuticals | Apr 6, 2027 | 734 |
| NCT06972212Pain Detection · New Zealand | Early 1 | Completed | Latigo Biotherapeutics | Jun 28, 2025 | 20 |
| NCT06887972Acute Pain · United States | 4 | Completed | Vertex Pharmaceuticals | Oct 24, 2025 | 100 |
| NCT06887959Acute Pain · United States | 4 | Completed | Vertex Pharmaceuticals | Oct 27, 2025 | 47 |
| NCT06834009Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Apr 24, 2025 | 10 |
| NCT06820307Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Apr 29, 2025 | 50 |
| NCT06696443Diabetic Peripheral Neuropathic Pain · United States | 3 | Active, not recruiting | Vertex Pharmaceuticals | Jan 25, 2027 | 455 |
| NCT06628908Diabetic Peripheral Neuropathic Pain · United States | 3 | Recruiting | Vertex Pharmaceuticals | May 31, 2027 | 1,100 |
| NCT06420765Pain · United Kingdom | 1 | Completed | Vertex Pharmaceuticals | Mar 22, 2025 | 92 |
| NCT06336096Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jun 19, 2024 | 48 |
| NCT06176196Painful Lumbosacral Radiculopathy · United States | 2 | Completed | Vertex Pharmaceuticals | Oct 2, 2024 | 218 |
| NCT05851157Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Oct 30, 2023 | 73 |
| NCT05818852Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jun 12, 2023 | 72 |
| NCT05704556Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Mar 30, 2024 | 38 |
| NCT05661734Pain · United States | 3 | Completed | Vertex Pharmaceuticals | Dec 12, 2023 | 258 |
| NCT05660538Diabetic Peripheral Neuropathy · United States | 2 | Completed | Vertex Pharmaceuticals | Oct 12, 2023 | 194 |
| NCT05635110Pain · Australia | 1 | Completed | Vertex Pharmaceuticals | Jun 8, 2023 | 31 |
| NCT05560464Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jul 24, 2023 | 36 |
| NCT05558410Acute Pain · United States | 3 | Completed | Vertex Pharmaceuticals | Aug 25, 2023 | 1,118 |
| NCT05553366Acute Pain · United States | 3 | Completed | Vertex Pharmaceuticals | Dec 15, 2023 | 1,075 |
| NCT05541471Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Apr 16, 2023 | 37 |
| NCT05455502Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Sep 17, 2022 | 24 |
| NCT05034952Acute Pain · United States | 2 | Completed | Vertex Pharmaceuticals | Dec 5, 2021 | 303 |
| NCT04977336Acute Pain · United States | 2 | Completed | Vertex Pharmaceuticals | Feb 17, 2022 | 274 |
How it is read
Names in the registry
- “Suzetrigine”, 13 entries
- “VX-548”, 11 entries
- “SUZ”, 2 entries
- “suzetrigine 100mg”, 1 entry
- “Suzetrigine (SUZ)”, 1 entry
Codes read as this program: VX548.
Conditions, from the studies’ own filings
- Pain, 16 studies
- Acute Pain, 6 studies
- Neuralgia, 3 studies
- Radiculopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.